LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas
… programs supports ProQR’s strategic focus on Axiomer® RNAediting platform technology and continued advancement of … of its Axiomer RNAediting platform at the RNAEditingSummit in Boston. The presentation described ongoing efforts …
… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … Chan Medical School, Worcester July 11-13, RNAEditingSummit, Boston Financial Highlights At March 31, 2023, …
AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and trial design details to be announced in H2 2024$4.5 million in milestones
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas … Seventh Annual Retinal Cell and Gene Therapy Innovation Summit, April 29, 2022, and the Association for Research in …